Bard to acquire Impra
This article was originally published in Clinica
CR Bard is to acquire privately-owned Impra, a producer of PTFE (Teflon) vascular grafts for blood vessel replacement surgery. Terms of the cash merger, which is expected to close in the third quarter, have not been disclosed. Impra, which has estimated annual sales of $50-55 million, has over 260 commercial vascular products and is developing vascular graft and endovascular technologies. It is also collaborating with Sulzer subsidiary Vascutek on surface modification technologies (see Clinica No 680, p 20).